Medical devices maker Smith and Nephew said that its Bioventus joint venture with Essex Woodlands is now up and running.
Essex Woodlands, a specialist healthcare growth equity and venture capital firm, pitched in with Smith & Nephew (S&N) to further develop the S&N's Biologics and Clinical Therapies division.
The alliance was announced at the beginning of the year but was subject to obtaining required regulatory approvals and satisfaction of other customary conditions.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Essex Woodlands owns 51% of Bioventus with the rest owned by S&N.
JH
-
Cash in on the growth prospects of Europe's companiesOpinion Marcel Stötzel, co-portfolio manager of the Fidelity European Trust, selects three stocks
-
Is the AI boom another dotcom bubble?25 years on from the dotcom bubble bursting, is it time for investors to consider the sustainability of the AI boom in the stock market?
